2seventy bio Stock (NASDAQ:TSVT)
Previous Close
$4.97
52W Range
$2.29 - $5.30
50D Avg
$3.86
200D Avg
$4.01
Market Cap
$256.39M
Avg Vol (3M)
$1.25M
Beta
1.05
Div Yield
-
TSVT Company Profile
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.
TSVT Performance
Peer Comparison
| Ticker | Company |
|---|---|
| MRSN | Mersana Therapeutics, Inc. |
| IOVA | Iovance Biotherapeutics, Inc. |
| KZR | Kezar Life Sciences, Inc. |
| SRPT | Sarepta Therapeutics, Inc. |
| ZNTL | Zentalis Pharmaceuticals, Inc. |
| RCUS | Arcus Biosciences, Inc. |
| RLAY | Relay Therapeutics, Inc. |
| CRNX | Crinetics Pharmaceuticals, Inc. |
| STOK | Stoke Therapeutics, Inc. |
| DAWN | Day One Biopharmaceuticals, Inc. |
| PLRX | Pliant Therapeutics, Inc. |
| SNDX | Syndax Pharmaceuticals, Inc. |
| PBYI | Puma Biotechnology, Inc. |
| REPL | Replimune Group, Inc. |
| CGEM | Cullinan Oncology, Inc. |
| PHAT | Phathom Pharmaceuticals, Inc. |
| PTGX | Protagonist Therapeutics, Inc. |
| INZY | Inozyme Pharma, Inc. |
| ASND | Ascendis Pharma A/S |